Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

Spectranetics PELA Study Extended

Facebook Twitter LinkedIn Email Comments
COLORADO SPRINGS, Jan. 16 -- The Spectranetics Corp. said it has FDA approval to continue its peripheral excimer laser angioplasty (PELA) study, without the need to randomize patients. The study extension, PELA III, allows the excimer laser to be used to treat total occlusions at least 10 cm long of the main thigh artery for 120 additional patients at 21 sites. Patients will be enrolled in PELA III during the follow-up and approval phases of the PELA trial, which completed randomized patient enrollment in November, is on track to receive FDA approval in 2003, Spectranetics said.
Jan 2002
News & Features

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.